Pacific Biosciences of California Inc. (NASDAQ:PACB) does about 1.80M shares in volume on a normal day but saw 5881939 shares change hands in Tuesday trading. The company now has a market cap of 1.22B USD and an enterprise value of about $1.04B. Its current market price is $7.09, marking an increase of 7.50% compared to the previous close of $6.60. The 52 week high reached by this stock is $6.73 whilst the lowest price level in 52 weeks is $2.20. The script in recent trading has seen the stock touch a high of $7.25 and a low of $6.59.

Pacific Biosciences of California Inc. (PACB) has a 20-day trading average at $5.84 and the current price is 5.42% off the 52-week high compared with 222.50% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.62 and its 200-day simple moving average is $4.19. If we look at the stock’s price movements over the week, volatility stands at 5.66%, which increases to 6.60% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 78.71 to suggest the stock is overbought.

4 analysts observing the Pacific Biosciences of California Inc. (PACB) stock have set the 12-month price targets for the company’s shares at between $5.00 and $8.00. The consensus objective for the share price is $6.33, suggesting that the stock has a potential downside of -12.01% over the period. The median price target is -28.91% away from the current levels at $5.50.

FactSet Research has provided data showing that 4 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 02, 2020 when Cantor Fitzgerald resumed the stock to “Overweight” and issued a price target of $5. Piper Jaffray upgraded its price target at $8.

The current price level is 24.96%, 55.98%, and 69.70% away from its SMA20, SMA50, and SMA200 respectively, with the PACB price moving below the 50-day SMA on September 01. Pacific Biosciences of California Inc. (PACB) stock is up 10.00% over the week and 81.46% over the past month. Its price is 38.04% year-to-date and 26.02% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.15 above consensus estimates by $0.03. The company’s next earnings report is expected on 10/29/2020, with forecasts estimating quarterly EPS at -$0.14 and -$0.11 for whole year. PACB’s earnings per share are forecast to grow by 80.00% this year and -336.40% over next year. Expected sales for next quarter are $26.74 million, which analysts say will come at $79.64 million for the current fiscal year and next year at $130.73 million. In addition, estimates put the company’s current quarterly revenue at an average of $20.13 million.

Its 12-month price target is $5.50. To reach the target analysts have set, the stock logically needs to shrink -12.01 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $8.00.

Outstanding shares total 154.17M with insiders holding 4.33% of the shares and institutional holders owning 87.94% of the company’s common stock. The company has a return on investment of -116.60% and return on equity of -98.30%. The beta has a value of 1.96. Price to book ratio is 26.28 and price to sales ratio is 14.73.

According to a U.S. Securities and Exchange Commission filing, American Funds Small Cap World Fu has reduced its position in Pacific Biosciences of California Inc. (PACB) to 12,242,300 shares, mirroring a recent drop by 0.00%. American Funds Small Cap World Fu dumped 0.0 shares of Pacific Biosciences of California Inc. common stock bringing its total worth to about $45.66 million at the end of recent close, SEC documents show. American Funds Small Cap World Fu isn’t the only investment manager who changed stakes and is followed by ARK Genomic Revolution ETF, which added 33130.0 shares to end up with 10,152,560 shares worth $37.87 million. Vanguard Total Stock Market Index cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 2.62% position in Pacific Biosciences of California Inc. thanks to 4.05 million shares amounting to $15.1 million.